Premium
Life under the CABOSUN: Cabozantinib improves quality‐adjusted survival in comparison with sunitinib
Author(s) -
AragonChing Jeanny B.,
Madan Ravi A.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33168
Subject(s) - sunitinib , medicine , cabozantinib , renal cell carcinoma , quality of life (healthcare) , oncology , toxicity , disease , clinical trial , intensive care medicine , nursing
Quality‐of‐life analyses such as this one for the Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) help to better define the relative impact of treatments beyond disease progression metrics, including socioeconomics. Although there are no head‐to‐head comparisons of the recent major clinical trials demonstrating efficacy in first‐line therapy for intermediate‐ or poor‐risk metastatic renal cell carcinoma, data from quality‐adjusted time without symptoms of disease or toxicity analyses can be used to also determine potential quality‐of‐life gains and toxicity.